Janus Henderson Group PLC Buys 566,146 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Janus Henderson Group PLC boosted its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 8.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 7,379,309 shares of the company’s stock after purchasing an additional 566,146 shares during the period. Janus Henderson Group PLC owned approximately 0.07% of Dyne Therapeutics worth $173,808,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. Jefferies Financial Group Inc. bought a new stake in Dyne Therapeutics in the fourth quarter worth about $42,408,000. Ensign Peak Advisors Inc increased its stake in shares of Dyne Therapeutics by 0.9% in the fourth quarter. Ensign Peak Advisors Inc now owns 315,602 shares of the company’s stock worth $7,436,000 after purchasing an additional 2,850 shares in the last quarter. Frontier Capital Management Co. LLC purchased a new position in shares of Dyne Therapeutics in the fourth quarter worth about $7,022,000. Deutsche Bank AG increased its stake in shares of Dyne Therapeutics by 51.4% in the fourth quarter. Deutsche Bank AG now owns 70,961 shares of the company’s stock worth $1,672,000 after purchasing an additional 24,104 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. increased its stake in shares of Dyne Therapeutics by 83.1% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 133,772 shares of the company’s stock worth $3,152,000 after purchasing an additional 60,732 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Insider Transactions at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders sold 6,237 shares of company stock worth $77,760. 14.14% of the stock is currently owned by insiders.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $11.44 on Monday. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -3.21 and a beta of 1.19. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $47.45. The firm has a 50 day moving average price of $10.37 and a 200-day moving average price of $17.98.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.17). As a group, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Wall Street Analyst Weigh In

DYN has been the subject of several recent research reports. JPMorgan Chase & Co. reduced their target price on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, March 21st. Scotiabank assumed coverage on shares of Dyne Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Piper Sandler reduced their price objective on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Finally, Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.85.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.